Completing one last deal before finalizing its merger with Merck KGaA, Serono SA gained exclusive rights from Newron Pharmaceuticals SpA to safinamide, a compound undergoing a Phase III trial in Parkinson's disease, for up to $200 million. (BioWorld International) Read More
